proteins and the prediction of a protein’s shape computationally rather than determining it
experimentally through years of laborious and often costly techniques.
Companies applying AI to biotechnology and biomanufacturing can benefit from the
measures proposed in the AI package
38
, especially from the setting up of AI Factories which
will give privileged access to supercomputers to AI startups and the broader innovation
community. Companies could also benefit from the strengthened support to the Common
European Data Spaces, and the launch of “GenAI4EU”, a landmark initiative that has
earmarked approximately EUR 500 million to stimulate the uptake of generative AI across
all of the Union’s fourteen industrial ecosystems, including biotechnology.
The European Health Data Space Regulation (EHDS) once applicable will standardise health
data across the EU to allow for better use for research, innovation, and public health policies
(the “secondary use of health data”). While protecting patients’ fundamental right to privacy,
the EHDS will facilitate access to and use of health data, including their use for the purposes
of R&D for health biotech in particular, in a secure and trustworthy setting.
The '1+ Million Genomes' (1+MG) initiative
39
aims to enable secure access to genomics and
the corresponding clinical data across Europe for better research, personalised healthcare
and health policy making. Its Genomic Data Infrastructure will establish a federated data
infrastructure for genomic and clinical data across Europe. Since November 2023, the 1+MG
initiative is in its second (scale-up and sustainability) phase, implementing the technical
infrastructure, initial infrastructure operation with research pilots in clinical use-cases, and
connection of the infrastructure to EHDS. By 2026, 15 countries will have an operational
infrastructure in place. An integrated cross-country data infrastructure can be used to expand
to collection of new biomarkers (e.g. lifestyle/environment biomarkers beyond health, such
as air quality, labour characteristics) and more comprehensive datasets needed for precision
medicine and longevity research.
The Commission will take the following actions to foster the application of big data and AI
in biotech and biomanufacturing companies:
• In the context of the GenAI4EU initiative, support structured exchanges with
stakeholders to accelerate the uptake of AI, and in particular Generative AI, in biotech
and biomanufacturing and raise awareness with those stakeholders of facilitated access
to the EuroHPC supercomputers for AI startups and the science and innovation
community.
• Support the development of advanced Generative AI models for healthcare,
leveraging data and tools such as multi-modal data and human health 'Virtual Human
Twin'
40
modelling, existing cross-border data infrastructures
41
and other relevant data
sources, supported under the Horizon Europe and Digital Europe programmes and using
Euro HPC supercomputing capacities.